New RAD202 data confirms positive tumor uptake

New RAD202 data confirms positive tumor uptake

Radiopharm Theranostics (RAD:AU) has announced New RAD202 data confirms positive tumor uptake

Download the PDF here.

The Conversation (0)
Appendix 4E and Preliminary Final Report

Appendix 4E and Preliminary Final Report

Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
RAD receives IND approval from US FDA for Betabart (RV-01)

RAD receives IND approval from US FDA for Betabart (RV-01)

Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2026

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind,... Keep Reading...
Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Enters a Material Transfer Agreement With PegBio

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's... Keep Reading...
Person in blue scrubs interacts with a digital interface featuring graphs and medical icons.

Biotech and Pharma Market Trends: Q2 2026 Review and Forecast

Biotech is starting to edge back into focus as investors reassess the durability of the artificial intelligence (AI) trade and look for sectors where AI is producing tangible operational gains. “There are concerns that we’re in an AI bubble, and I think money is starting to go from companies... Keep Reading...
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks in 2026

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has climbed back to multi-year highs in 2026, underscoring renewed strength in the biotech sector despite broader market volatility. As of July 7, the index stood at 6,856.74, up over 20 percent year-to-date. The rise shows that investors are... Keep Reading...
Lexaria Updates Business Development

Lexaria Updates Business Development

(TheNewswire) Kelowna, British Columbia July 6, 2026 TheNewswire Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at... Keep Reading...
Lexaria Updates Business Development

Lexaria Updates Business Development

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO... Keep Reading...

Interactive Chart

Latest Press Releases

Related News